Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Disability in Patients With Osteoarthritis
NCT ID: NCT01137266
Last Updated: 2010-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
72 participants
INTERVENTIONAL
2008-07-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. the location with the lowest resistance
2. the location that causes an irradiation sensation
3. a random stimulation site (but within a 10x10cm area of the irradiation site). The effect is defined as the pain VAS baseline-measurement before treatment minus the pain VAS repeat-measurement after the given treatment
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rationale: In clinical practice the position of TENS electrodes appears to be critical to success. It is claimed that electrodes should target areas with high neural density and where nerve bundles come close to the body surface. These areas are likely to have low skin resistances. Research in the field of electro-analgesia suggests areas of low skin resistance are linked to TENS stimulation points, and that this lower skin resistance may reflect areas with a higher density of neural tissue. When stimulated these areas are likely to generate larger nerve activity and potentially a greater analgesic outcome. For this reason many acupuncturist use a point finder to locate the optimal site to insert the acupuncture needle. To date the relationship between the skin resistance of the areas stimulated by TENS and pain relief is not known.
At present, optimal sites for electrode positioning is made ad hoc using a trial and error approach. This may result in electrodes being positioned at sub-optimal sites. The Philips new electronic pain relief device contains an array, or matrix, of small electrodes. Using this array, the device can measure electrical skin properties. In addition, the user can select which electrodes in the array are active and can adjust the intensity of those electrodes so that stimulation can be targeted to a specific location. In this way it is possible to investigate whether stimulating areas of low skin resistance has an effect on pain relief.
With a novel matrix TENS electrode we would like to investigate the TENS outcome for different electrode specifically chosen locations versus randomly chosen locations. Randomly chosen locations are defined as an area of approximately 10x10 cm around the specifically chosen location in which the random simulation point is chosen. The outcome of the specific vs. random stimulation will be measured with as primary outcome pain and mobility and as secondary outcome strength, joint range, and quality of life.
Objective: Determine effects of transcutaneous electrical nerve stimulation (TENS) on pain and mobility by comparing different stimulation sites; 1) the location with the lowest resistance, 2) the location that causes an irradiation sensation, 3) a random stimulation site (but within a 10x10cm area of the irradiation site). The effect is defined as the pain VAS baseline-measurement before treatment minus the pain VAS repeat-measurement after the given treatment
Study design: double-blind intervention study
Study population: Patients with chronic pain arise from osteo-arthritis in one or both knees Age (\>18y), sex and ethnic background are not relevant
Intervention (if applicable): Patients receive a 3 times 30 minutes TENS treatment.
Main study parameters/endpoints: The primary outcome parameters are pain (VAS) and mobility (PDI and 6 min walk). Secondary outcome parameters are strength (MVC) and range-of-motion (ROM) in knee extension and quality of life (SF36).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is no risk for the patients. The burden for the participants is 3 times 1 hour.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
skin resistence
1\) the location with the lowest resistance
TENS
TENS
irradiation
2\) the site that causes an irradiation sensation
TENS
TENS
random
3\) a random stimulation site.
TENS
TENS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TENS
TENS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least 18 years old
* VAS higher than 40mm, lower than 70mm (on a 100 mm VAS scale) at the moment of the investigation
* pain symptoms duration longer than 3 months
Exclusion Criteria
* unable to co-operate
* malignancy
* recent bleeding tissue or haemorrhage in knee
* epilepsy
* advanced cardiovascular conditions, e.g. severe angina or cardiac arrhythmias
* Pacemakers or cochlear implants
* pregnant
* sensory loss of the area to be treated
* devitalised skin e.g. after recent radiotherapy;
* local acute skin conditions e.g. eczema, dermatitis
* doubtful diagnoses
* global, multiple location pain (other than both knees)
* people who undergo currently a TENS treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Electronics Nederland BV
INDUSTRY
Maxima Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Philips Research Eindhoven
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
A Kolen, PhD
Role: PRINCIPAL_INVESTIGATOR
Philips Research Eindhoven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maxima Medical Centre
Eindhoven, North Brabant, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL2073208008
Identifier Type: -
Identifier Source: org_study_id